Pharmaceuticals News and Research

RSS

Odd foreign bodies removed from patients

Sermo, the world's largest online community for physicians, today announced its weekly hot topic. Of over 200 physician respondents to an online poll and discussion, 85% said they have removed odd foreign bodies from patients.

6 Oct 2010

European infertility patients are limited in choice for medically assisted reproduction treatment

In a number of European countries, infertility patients are limited in their choice for medically assisted reproduction treatment, experts criticized today at the European Health Forum Gastein. Many patients seek treatment outside their home countries.

6 Oct 2010

Michael J. Fox Foundation for Parkinson's Research announces awards totaling $10.1M

The Michael J. Fox Foundation for Parkinson's Research announced awards totaling approximately $10.1 million for five new clinical studies and 14 pre-clinical therapeutic development projects. The funding includes $2.5 million to drive four new clinical trials under the Clinical Intervention Awards, one of the Foundation's Edmond J. Safra Core Programs for PD Research.

6 Oct 2010

Nautilus Neurosciences announces exclusive co-promotion agreement for CAMBIA drug

Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company, and Mission Pharmacal Company, a privately-held pharmaceutical company focused on the women's health market announced today their exclusive co-promotion agreement for CAMBIA (diclofenac potassium for oral solution) to obstetrician's, gynecologists and other women's health medical professionals.

6 Oct 2010

QSR Holdings represents former stockholders of Quill Medical

Angiotech Pharmaceuticals, Inc. today announced that on October 4, 2010, the Company was notified that QSR Holdings, Inc. as the representative for the former stockholders of Quill Medical, Inc. made a formal demand to the American Arbitration Association naming as respondents the Company, together with its subsidiaries QMI and Angiotech Pharmaceuticals (US), Inc.

6 Oct 2010

CoreLab Partners completes first ever regulatory mandated Thorough QT study in the Asia Pacific Rim

CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm and Medifacts International in February of this year, has recently completed the first ever regulatory mandated Thorough QT (TQT) study conducted in the Asia Pacific Rim and the first TQT study for a Japanese new drug application (NDA).

6 Oct 2010

ESHRE workshop highlights problems related to MAR treatment in Europe

European patients are in many countries, in fact, limited in their individual choice of medically assisted reproduction (MAR) treatment, experts from the European Society of Human Reproduction and Embryology (ESHRE) stressed today at the European Health Forum Gastein (EHFG).

6 Oct 2010

Pfizer announces review of strategic alternatives for Capsugel

Pfizer Inc. announced today that it is reviewing strategic alternatives for Capsugel, which may include a divestiture. Capsugel is a distinct business unit within Pfizer's Diversified Businesses segment and is the world's leading provider of hard capsules and an innovator in drug delivery systems.

6 Oct 2010

Fisher Wallace Laboratories launches easy-to-use medical device for depression treatment

Fisher Wallace Laboratories today announced the launch of a bold YouTube video campaign that challenges the pharmaceutical drug industry and introduces the company's easy-to-use medical device prescribed for the self-treatment of depression: the Fisher Wallace Cranial Stimulator.

6 Oct 2010

ISTA Pharmaceuticals announces Phase 1/2 clinical study results of bepotastine besilate nasal spray

ISTA Pharmaceuticals, Inc., today announced positive preliminary results from a Phase 1/2 clinical study of bepotastine besilate nasal spray conducted in Canada for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies.

6 Oct 2010

Synergy reports positive results from plecanatide Phase IIa clinical trial for chronic constipation

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today positive results in a Phase IIa clinical trial of plecanatide (SP-304) in patients with chronic constipation. Oral plecanatide given once daily, over 14 consecutive days, at doses of 0.3, 1.0, 3.0 and 9.0 mg gave improved bowel function in patients with chronic constipation.

6 Oct 2010

Adeona completes enrollment in Part 2 CopperProof-2 clinical study

Adeona Pharmaceuticals, Inc., announced completion of 100% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease (CopperProof-2).

6 Oct 2010

Pathwork Diagnostics closes $30M Series C financing

Pathwork Diagnostics, Inc, a privately held molecular diagnostics company focused on oncology, today announced the closing of its $30 million Series C financing. Led by Alta Partners, the financing included participation from the company's existing investors: Abingworth, Advent Venture Partners, Novus Ventures, Prospect Venture Partners and Venrock.

6 Oct 2010

Research to focus on effective use of artemisinin stocks for malaria

The frontline malaria treatment artemisinin could soon be treating more people for less cost, thanks to a research collaboration between Bradford and Shanghai.

6 Oct 2010

Progress in predicting epileptic seizures

A team of physicists, physicians and neuroscientists at the Bernstein Center of the University Freiburg did a step forward towards the ambitious goal of predicting epileptic seizures, as published in the latest issue of the journal "Epilepsia".

6 Oct 2010

Johnson & Johnson to acquire all outstanding equity of Crucell for euro 1.75 billion

Johnson & Johnson and Crucell N.V. today announced an agreement whereby Johnson & Johnson, through an affiliate, would acquire all outstanding equity of Crucell that it does not already own for approximately euro 1.75 billion in a recommended cash tender offer.

6 Oct 2010

Aegerion Pharmaceuticals’ MTP-I Phase III trial published in Atherosclerosis online supplement

ACR Image Metrix, a global imaging contract research organization (CRO) with expertise in imaging trial design, techniques and data extraction, is pleased to announce a Phase III trial, conducted for Aegerion Pharmaceuticals, Inc., was published as an abstract in the online supplement of Atherosclerosis and presented at the 78th European Atherosclerosis Society Congress, which took place June 20-23, 2010, in Hamburg, Germany.

6 Oct 2010

Xeomin botulinum toxin for cervical dystonia now available in the U.S.

Merz Pharmaceuticals today announced that Xeomin (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010.

6 Oct 2010

New Wipro Rapid Trials platform launched to accelerate drug development

Wipro Technologies, the global Consulting, System Integration and Outsourcing business of Wipro Limited, today announced the launch of Wipro Rapid Trials platform to accelerate drug development across the globe.

6 Oct 2010

Watson seeks FDA approval to market rasagiline mesylate tablets

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rasagiline mesylate 0.5 and 1.0 mg tablets.

6 Oct 2010

Pharmaceuticals News and Research

Odd foreign bodies removed from patients

European infertility patients are limited in choice for medically assisted reproduction treatment

Michael J. Fox Foundation for Parkinson's Research announces awards totaling $10.1M

Nautilus Neurosciences announces exclusive co-promotion agreement for CAMBIA drug

QSR Holdings represents former stockholders of Quill Medical

CoreLab Partners completes first ever regulatory mandated Thorough QT study in the Asia Pacific Rim

ESHRE workshop highlights problems related to MAR treatment in Europe

Pfizer announces review of strategic alternatives for Capsugel

Fisher Wallace Laboratories launches easy-to-use medical device for depression treatment

ISTA Pharmaceuticals announces Phase 1/2 clinical study results of bepotastine besilate nasal spray

Synergy reports positive results from plecanatide Phase IIa clinical trial for chronic constipation

Adeona completes enrollment in Part 2 CopperProof-2 clinical study

Pathwork Diagnostics closes $30M Series C financing

Research to focus on effective use of artemisinin stocks for malaria

Progress in predicting epileptic seizures

Johnson & Johnson to acquire all outstanding equity of Crucell for euro 1.75 billion

Aegerion Pharmaceuticals’ MTP-I Phase III trial published in Atherosclerosis online supplement

Xeomin botulinum toxin for cervical dystonia now available in the U.S.

New Wipro Rapid Trials platform launched to accelerate drug development

Watson seeks FDA approval to market rasagiline mesylate tablets

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence